IP Library › Granted Patent US 12,552,869
Granted Patent B2
US 12,552,869 · App. 17/783,552 · Granted Feb 17, 2026

CSF-1R antibodies for the treatment of chronic graft versus host disease

Inventors: Peter Ordentlich (Lexington, MA); Michael Meyers (Hastings-on-Hudson, NY); Briggs W. Morrison (Newtown, PA)
Assignee: Syndax Pharmaceuticals, Inc.
C07K16/2866A61K39/3955A61P37/06A61K2039/505A61K2039/545C07K2317/24C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,552,869
App. No.
17/783,552
Granted
Feb 17, 2026
Kind
B2
Abstract

The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab.

Claims (41)

1 . A method of treating chronic graft versus host disease (cGVHD), wherein the method comprises intravenously administering an anti-CSF-1R antibody to a human subject in need thereof at a dose of 0.3 mg/kg every two weeks or 1.0 mg/kg every two weeks, wherein the anti-CSF-1R antibody comprises a light chain and a heavy chain, wherein:

a variable domain of the light chain comprises:

a CDR comprising the amino acid sequence SEQ ID NO: 1 for CDR-L1,

a CDR comprising the amino acid sequence SEQ ID NO:2 for CDR-L2, and

a CDR comprising the amino acid sequence SEQ ID NO:3 for CDR-L3; and

a variable domain of the heavy chain comprises:

a CDR comprising the amino acid sequence SEQ ID NO:4 for CDR-H1,

a CDR comprising the amino acid sequence SEQ ID NO:5 for CDR-H2, and

a CDR comprising the amino acid sequence SEQ ID NO:6 for CDR-H3.

2 . The method of claim 1 , wherein:

the heavy chain comprises the amino acid sequence SEQ ID NO:23; and

the light chain comprises the amino acid sequence SEQ ID NO:15.

3 . The method of claim 1 , wherein the heavy chain comprises the amino acid sequence SEQ ID NO:27 and the light chain comprises the amino acid sequence SEQ ID NO:19.

4 . The method of claim 1 , wherein the chronic graft versus host disease is selected from skin chronic graft versus host disease, eyes chronic graft versus host disease, mouth chronic graft versus host disease, esophagus chronic graft versus host disease, upper GI chronic graft versus host disease, lower GI chronic graft versus host disease, liver chronic graft versus host disease, lungs chronic graft versus host disease, joints and fascia chronic graft versus host disease, and global chronic graft versus host disease.

5 . The method of claim 4 , wherein the cGVHD in the human subject has progressed on one or more prior therapies.

6 . The method of claim 5 , wherein the cGVHD in the human subject has progressed from a previous ibrutinib treatment.

7 . The method of claim 5 , wherein the cGVHD in the human subject has progressed on at least two prior therapies, wherein at least one prior therapy was ibrutinib.

8 . The method of claim 5 , wherein the method decreases a level of non-classical, intermediate, and/or classical monocytes, and wherein the level of non-classical, intermediate, and/or classical monocytes is not fully depleted between doses of the anti-CSF-1R antibody.

9 . The method of claim 1 , wherein the anti-CSF-1R antibody is axatilimab.

10 . The method of claim 1 , wherein the cGVHD is sclerodermatous.

11 . The method of claim 3 , wherein the heavy chain C-terminal lysine is absent.

12 . The method of claim 1 , wherein the method further comprises administering a second therapeutic agent.

13 . The method of claim 12 , wherein the second therapeutic agent is a corticosteroid.

14 . A method of treating cGVHD in a human subject in need thereof, the method comprising intravenously administering an anti-CSF-1R antibody comprising a heavy chain comprising an amino acid sequence SEQ ID NO: 27 and a light chain comprising the amino acid sequence SEQ ID NO: 19 at a dose of 0.3 mg/kg every two weeks.

15 . The method of claim 14 , wherein the heavy chain C-terminal lysine is absent.

16 . The method of claim 14 , wherein the cGVHD is selected from skin chronic graft versus host disease, eyes chronic graft versus host disease, mouth chronic graft versus host disease, esophagus chronic graft versus host disease, upper GI chronic graft versus host disease, lower GI chronic graft versus host disease, liver chronic graft versus host disease, lungs chronic graft versus host disease, joints and fascia chronic graft versus host disease, and global chronic graft versus host disease.

17 . A method of treating cGVHD in a human subject in need thereof, the method comprising intravenously administering an anti-CSF-1R antibody comprising a heavy chain comprising a sequence given in SEQ ID NO: 27 and a light chain comprising a sequence given in SEQ ID NO:19 at a dose of 1.0 mg/kg every two weeks.

18 . The method of claim 17 , wherein the heavy chain C-terminal lysine is absent.

19 . The method of claim 17 , wherein the chronic graft versus host disease is selected from skin chronic graft versus host disease, eyes chronic graft versus host disease, mouth chronic graft versus host disease, esophagus chronic graft versus host disease, upper GI chronic graft versus host disease, lower GI chronic graft versus host disease, liver chronic graft versus host disease, lungs chronic graft versus host disease, joints and fascia chronic graft versus host disease, and global chronic graft versus host disease.

20 . The method of claim 1 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a partial response, a complete response, or the cGVHD has not progressed.

21 . The method of claim 1 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a partial response for at least twenty weeks.

22 . The method of claim 1 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a complete response for at least twenty weeks.

23 . The method of claim 1 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the cGVHD has not progressed for at least twenty weeks.

24 . The method of claim 14 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a partial response, a complete response, or the cGVHD has not progressed.

25 . The method of claim 14 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a partial response for at least twenty weeks.

26 . The method of claim 14 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a complete response for at least twenty weeks.

27 . The method of claim 14 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the cGVHD has not progressed for at least twenty weeks.

28 . The method of claim 17 further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a partial response, a complete response, or the cGVHD has not progressed.

29 . The method of claim 17 , further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a partial response after at least twenty weeks.

30 . The method of claim 17 , further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the subject has a complete response for at least twenty weeks.

31 . The method of claim 17 , further comprising administering the anti-CSF-1R antibody at a dose of 0.6 mg/kg every four weeks once the cGVHD has not progressed for at least twenty weeks.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2023
From: ORDENTLICH, PETER; MEYERS, MICHAEL; MORRISON, BRIGGS W.
To: SYNDAX PHARMACEUTICALS, INC.
Reel/Frame 062588/0592 →
Continuity (3)
Provisional Application 63110111 · Nov 5, 2020
Provisional Application 62945842 · Dec 9, 2019
Related Publication 20230035183A1 · Feb 2, 2023
References Cited (106)
US 8017739B2 · Eichner et al. · 2011 [cited by applicant]
US 9908939B2 · Craggs et al. · 2018 [cited by applicant]
US 10039826B2 · Boonen et al. · 2018 [cited by applicant]
US 10421814B2 · Craggs et al. · 2019 [cited by applicant]
US 20070086979A1 · Chevrier et al. · 2007 [cited by applicant]
US 20090148905A1 · Ashman et al. · 2009 [cited by applicant]
US 20110178278A1 · Haegel et al. · 2011 [cited by applicant]
US 20130095098A1 · Tyson · 2013 [cited by applicant]
US 20160200820A1 · Marshall · 2016 [cited by applicant]
AR 079333A1 · 2012 [cited by applicant]
CN 1863817A · 2006 [cited by applicant]
CN 101128484A · 2008 [cited by applicant]
WO WO03080672A1 · 2003 [cited by applicant]
WO WO2006072093A2 · 2006 [cited by applicant]
WO WO2007143146A2 · 2007 [cited by applicant]
WO WO2008055013A2 · 2008 [cited by applicant]
WO WO2009026303A1 · 2009 [cited by applicant]
WO WO2009052237A1 · 2009 [cited by applicant]
WO WO2009112245A1 · 2009 [cited by applicant]
WO WO2010012667A1 · 2010 [cited by applicant]
WO WO2011070024A1 · 2011 [cited by applicant]
WO WO2011107553A1 · 2011 [cited by applicant]
WO WO2011123381A1 · 2011 [cited by applicant]
WO WO2011131407A1 · 2011 [cited by applicant]
WO WO2011140249A2 · 2011 [cited by applicant]
WO WO2012082689A1 · 2012 [cited by applicant]
WO WO2012110360A1 · 2012 [cited by applicant]
WO WO2013057281A2 · 2013 [cited by applicant]
WO WO2013087699A1 · 2013 [cited by applicant]
WO WO2013119716A1 · 2013 [cited by applicant]
WO WO2014036076A1 · 2014 [cited by applicant]
WO WO2015028454A2 · 2015 [cited by applicant]
WO WO2015028455A1 · 2015 [cited by applicant]
WO WO2016128318A1 · 2016 [cited by applicant]
WO WO2018213665A1 · 2018 [cited by examiner]
Pitiot et al.. Alternative Routes of Administration for Therapeutic Antibodies—State of the Art, Antibodies, 11(3):56, 25 pages, doi: 10.3390/antib11030056, Aug. 22, 2022. [cited by examiner]
Ordentlich et al., Targeting colony stimulating factor-1 receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R targeted antibody, Retrieved online from:<URL:https://cms.syndax.com/wp- content/uploads/2016/11/SITC_2016_6… [cited by examiner]
Sarantopoulos, S, Targeting CSF1R in chronic GVHD—Lessons in translation, New Engl. J. Med. 391(11):1053-1055, Sep. 19, 2024. [cited by examiner]
Ahmed et al., Phase Ib/Il Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies, J. Immunother. Prec. Oncol. 27(2):73-81, May 2024. [cited by examiner]
ClinicalTrials.gov Database, NCT03604692, A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD, ver.2, Retrieved online from: <URL:https://clinicaltrials.gov/study/NCT03604692?term=nct03604692&rank… [cited by examiner]
DrugBank Database, Axatilimab, https://go.drugbank.com/drugs/DB16388> [retrieved on Apr. 30, 2025], Oct. 2, 2024. [cited by examiner]
Wolff et al., Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease, N. Engl. J. Med. 391:1002-14, 2024. [cited by examiner]
Baran et al. “Important Roles for Macrophage Colony-stimulating Factor, CC Chemokine Ligand 2, and Mononuclear Phagocytes in the Pathogenesis of Pulmonary Fibrosis”, Am. J. Respir. Grit. Care Med., (2007); 176:78-89. [cited by applicant]
Chen, C. et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial association”, EMBO J. Jun. 15, 1995; 14(12): 2784-94. [cited by applicant]
Colman, P. M., “Effects of amino acid sequence changes on antibody-antigen interactions”, Res Immunol. Jan. 1994; 145(1): 33-6. [cited by applicant]
International Preliminary Report of International Application No. PCT/EP2014/068050, dated Mar. 1, 2016, 8 pages. [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/EP2014/068047, mailed Mar. 30, 2015, 19 pages. [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/EP2014/068050, mailed Nov. 6, 2014, 13 pages. [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/EP2016/052494, mailed Apr. 5, 2016, 11 pages. [cited by applicant]
Kussie, P. H. et al. “A single engineered amino acid substitution changes antibody fine specificity,” J. Immunol., (1994); 152:146-152. [cited by applicant]
Lim et al. “Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice”, Diabetologia; (May 23, 2009); 52(8):1669-1679. [cited by applicant]
MacDonald et al. “An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation”, Blood, American S… [cited by applicant]
Maurer et al. “Emerging targeted therapies in scleroderma lung and skin fibrosis”, Bailliere's Best Practice and Research Clinical Reumatology, (2011); 25(6):843-858. [cited by applicant]
Paulus et al. “Colony-Stimulating Factor-1 Antibody Reverses Chemoresistance in Human MCF-7 Breast Cancer Xenografts”, Cancer Research, (Apr. 15, 2006); 66(8):4349-4356. [cited by applicant]
Pedroza, M. et al. “Interleukin-6 Contributes to Inflammation and Remodeling in a Model of Adenosine Mediated Lung Injury” PLoS ONE, (2011); 6(7):1-13. [cited by applicant]
Raghu et al., “Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone”, Am. J. Respir. Crit. Care Med., (1999); 159:1061-1069. [cited by applicant]
Rudikoff, S. et al. “Single amino acid substitution altering antigen-binding specificity”, Proc Natl Acad Sci, (Mar. 1982); 79:1979-1983. [cited by applicant]
Tamura, M., et al., “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,” … [cited by applicant]
Wedge, S.R., et al.; “AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer,” Cancer Res. (2005); 65(10):4389-4400. [cited by applicant]
Byren, A.J., et al., “Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?”, Trends Mol Med., (2016); 22(4):303-316. [cited by applicant]
He, C., et al., “Accelerated development of pulmonary fibrosis via Cu,Zn-superoxide dismutase-induced alternative activation of macrophages”, J Biol Chem., (2013); 288(28):20745-20757. [cited by applicant]
Jiang, G. et al., “Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies,” J Pharm Sci. (2016); 105(7):2066-2072. [cited by applicant]
Pechkovsky, D.V., et al., “Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction,” Clin Immunol., (2010); 137(1):89-101. [cited by applicant]
Salmasian H, et.al., “Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation,” Cochrane Database Syst Rev. (2010), 15 pages. [cited by applicant]
Wynn, T.A., et al., “Macrophages: master regulators of inflammation and fibrosis,” Semin Liver Dis., (2010); 30(3):245-257. [cited by applicant]
Xiulan et al., “119 Establishment of hybridoma clones secreting CSF-1 receptor antibodies and the biological effects of monoclonal antibodies,” Journal of Cellular and Molecular Immunology, Issue 3, pp. 75-76 (1991), wi… [cited by applicant]
Alexander et al. “CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease” J Clin Invest. Oct. 2014;124(10):4266-80. [cited by applicant]
Arceci RJ et al. “Expression of CSF-1 /c-hs and SF/c-kit mRNA during Preimplantation Mouse Development”, Developmental Biology 1992, 151 (1), 1-8. [cited by applicant]
Arceci RJ “Temporal expression and location of colony-stimulating factor 1(CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development”, PNAS 1989, 86(22), 8818-882… [cited by applicant]
Byrne et al. “Distribution of Cells Bearing Receptors for a Colony-stimulating Factor (CSF-1) in Murine Tissues”, J Cell Biol 1981 91(3 Pt 1) 848-853. [cited by applicant]
Cerretti DP et al. “Human Macrophage-Colony Stimulating Factor: Alternative RNA and Protein Processing From a Single Gene”, Molecular Immunology, vol. 25, No. 8, pp. 761-770, 1988. [cited by applicant]
Crooks et al (1991) “The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients”, Journal of Gerontology: Medical Sciences, 1991, vol. 46. No. 4. M139-144. [cited by applicant]
Douglass TG et al. “Macrophage colony stimulating factor: Not just for macrophages anymore! A gateway into complex biologies”, 2008, International Immunopharmacology (2008) 8, 1354-1376. [cited by applicant]
Flowers M. E. and P. J. Martin (2015) “How we treat chronic graft-versus-host disease”, Blood 125(4): 606-615. [cited by applicant]
Hill et al. (2018) “New and emerging therapies for acute and chronic graft versus host disease”, Ther Adv Hematol 9(1): 21-46. [cited by applicant]
Hofstetter W et al. “Detection of Transcripts and Binding Sites for Colony-Stimulating Factor-1 During Bone Development”, Bone 1995, 17(2), 145-151. [cited by applicant]
Inamoto et al. (2020) “Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia”, Blood Advances 4(1): 40-46. [cited by applicant]
Jagasia et al. (2015) “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report”, Biol Bloo… [cited by applicant]
Jagasia et al. (2018) “Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials”, Immunotherapy 10(5): 391-402. [cited by applicant]
Jagasia et al. (2019) “Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD”, Blood Advances 3(14): 2218-2229. [cited by applicant]
Jokhi PP et al. “Expression of the Colony Stimulating Factor-I Receptor (c-fms Product) by Cells at the Human Uteroplacental Interface”, Laboratory Investigation 1993, 68(3), 308-320. [cited by applicant]
Kauma SW et al. “Colony-Stimulating Factor-1 and c-fms Expression in Human Endometrial Tissues and Placenta during the Menstrual Cycle and Early Pregnancy”, Journal of Clinical Endocrinology and Metabolism, 1991, 73(4),… [cited by applicant]
Lansky et al. (1987) “The measurement of performance in childhood cancer patients”, Cancer 60(7): 1651-1656. [cited by applicant]
Lee et al. (2002) “Development and validation of a scale to measure symptoms of chronic graft-versus-host disease”, Biology of Blood and Marrow Transplantation, 8(8): 444-452. [cited by applicant]
Lee et al. (2015) “Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I… [cited by applicant]
MacDonald K. P., (2017) “Chronic graft-versus-host disease: biological insights from preclinical and clinical studies”, Blood 129(1): 13-21. [cited by applicant]
Merkel et al. (2016) “Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews”, Biol Blood Marrow Transplant 22(4): 752-758. [cited by applicant]
Miklos et al. (2017) “Ibrutinib for chronic graft-versus-host disease after failure of prior therapy”, Blood 130(21): 2243-2250. [cited by applicant]
NCT03604692, A Phase 1/2 Study to Evaluate SNDX-6352 in Participants With Active cGVHD, dated Jul. 27, 2018, 10 pages. [cited by applicant]
O'Toole et al. (1991) “Evaluating cancer patients for rehabilitation potential”, The Western Journal of Medicine, 155(4): 384-387. [cited by applicant]
Pampfer S et al. “Expression of the Colony-Stimulating Factor-i Receptor (c-fms Proto-Oncogene Product) in the Human Uterus and Placenta”, Biology of Reproduction 1992, 46(1), 48-57. [cited by applicant]
Pixley FJ et al. “CSF-1 regulation of the wandering macrophage: complexity in action”, 2004, Trends in Cell Biology, 14(11) 628-38. [cited by applicant]
Pollard JW et al. “Pleiotropic Roles for CSF-1 in Development Defined by the Mouse Mutation Osteopetrotic”, Advances in Developmental Biochemistry vol. 4, 1996, pp. 153-193. [cited by applicant]
Regenstreif et al. “Expression of the c-fms Proto-oncogene and of the Cytokine, CSF-1, during Mouse Embryogenesis”, Developmental Biology 133, 284-294 (1989). [cited by applicant]
Schag et al. (1984) “Karnofsky performance status revisited: reliability, validity, and guidelines”, J Clin Oncol 2(3): 187-193. [cited by applicant]
Tanaka S et al. “Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors.”, 1993, The Journal of Clinical Investigation, 91: 257-263. [cited by applicant]
Teh et al. (2020) “Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale”, Biol Blood Marrow Transplant 26(3): 562-567. [cited by applicant]
Tey et al. “Chronic Graft-Versus-Host Disease: Therapeutics at Last?”, The Hematologist, Mini Review, Apr. 16, 2019, vol. 16, No. 3, 16 pages. [cited by applicant]
Thall et al. (1995) “Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes”, Statistics in Medicine 14(4): 357-379. [cited by applicant]
Weir EC et al. “Macrophage Colony-Stimulating Factor Release and Receptor Expression in Bone Cells” 1993, Journal of Bone and Mineral Research, 1993, 8(12) 1507-1518. [cited by applicant]
Arora, M., et al., “Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment,” (2020) Blood 136(Supplement 1):1-2, 5 pages. [cited by applicant]
Casadevall et al. “Immunoglobulin isotype influences affinity and specificity” Proceedings of the National Academy of Sciences (2012); 109(31):12272-12273. [cited by applicant]
NCT03604692 “A Phase 1/2 Study to Evaluate SNDX-6352 in Participants With Active cGVHD” Clinical Trials, dated Dec. 4, 2019, (Version 7) 18 pages. [cited by applicant]
Radojcic et al. “Safety, Tolerability, and Efficacy of Axatilimab, a Colony-Stimulating Factor 1 Receptor (CSF-1R) Humanized Antibody, in Advanced Chronic Graft-versus-host Disease-Related Bronchiolitis Obliterans Syndr… [cited by applicant]
Syndax Press Release “Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Session S… [cited by applicant]
Syndax Pharmaceuticals et al. “Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update” (May 8, 2023); 8 pages. Retrieved from the Internet: URL:https://www.prnewswi… [cited by applicant]